Tuesday, June 24, 2025

SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D

Related stories

Innovapptive Debuts 15 AI Agents for Plant Operations

Innovapptive is launching 15 AI agents that automate frontline...

Genasys & samdesk Partner for Real-Time Crisis Response

Genasys Inc., the global leader in Protective Communications, announced...

Caspia & Siemens Team Up to Boost Security with Gen AI

Caspia and Siemens are collaborating to add Caspia's portfolio...

Hexaware & Fixie.ai Partner to Boost Voice AI in Enterprise

Hexaware Technologies, a global provider of IT solutions and services,...

Datamaran Launches Core ESG & Reporting Intelligence Tool

Datamaran, the global leader in risk and governance intelligence...
spot_imgspot_img

SyntheticMR announced that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States.

SyntheticMR is proud to announce that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This milestone marks a significant advancement in quantitative MRI technology, offering unprecedented resolution and accuracy in brain imaging.

“We are thrilled to receive 510(k) clearance for SyMRI 3D,” says Ulrik Harrysson, CEO at SyntheticMR AB. “SyMRI 3D represents the next generation of quantitative MRI, revolutionizing the landscape of medical diagnostics and offering new possibilities for diagnosis and treatment.”

Also Read: Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.

“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging,” says Jared Dixon, President of SyntheticMR U.S Inc.

With this clearance, SyntheticMR reaffirms its commitment to advancing medical imaging technology and providing clinicians with innovative tools to enhance patient care. SyMRI 3D opens up new possibilities for precise diagnosis, treatment planning, and monitoring, ultimately improving patient outcomes.

SOURCE: SyntheticMR

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img